避孕藥具市場規模、佔有率和成長分析（按類型、通路和地區分類）－2026-2033年產業預測

預計到 2024 年，避孕藥具市場規模將達到 340.2289 億美元，到 2025 年將達到 362.3438 億美元，到 2033 年將達到 599.6775 億美元，在預測期（2026-2033 年將達到 59.6775 億美元，在預測期（2026-2033 年）年成長率為 6.5%。

避孕市場預計將受益於性行為感染發病率的上升以及越來越多的女性尋求避孕方法。在全球範圍內，許多育齡女性都表達了對計劃生育的需求，儘管目前已有數百萬女性使用避孕方法，但仍存在未被滿足的需求。旨在減少意外懷孕和提高人們對避孕選擇認知的有針對性的計畫預計將推動市場擴張。然而，人們對各種避孕方法可能產生的副作用（例如胃腸道問題、體重變化和情緒影響）的擔憂可能會阻礙市場成長。此外，已開發地區不孕症的上升和性教育的不均衡也對市場發展構成挑戰。

避孕藥具市場促進因素

全球貧困階級和低收入群體中意外懷孕的發生率尤其高。造成這問題的主要原因是依賴無效的傳統避孕方法，這會導致不安全墮胎和較高的孕產婦死亡率。在拉丁美洲等地區，年輕少女的孕產婦死亡風險顯著高於年長女性。因此，推廣避孕措施對於降低意外懷孕率、改善孕產婦健康以及為這些弱勢群體提供更好的生育選擇至關重要。

避孕藥市場限制

由於長期服用口服避孕藥會產生頭痛、不規則出血和噁心等副作用，避孕藥市場面臨嚴峻的挑戰。這些潛在的不良反應，尤其是在長期服用後，引發了消費者的擔憂。此外，含有雌激素和黃體素的藥物會增加血栓症形成的風險，進而導致心臟病發作等嚴重的健康併發症。因此，這些安全隱患導致消費者猶豫不決，可能阻礙避孕藥在市場上的擴張和普及，並限制其整體成長潛力。

避孕藥市場趨勢

避孕市場正經歷著向技術創新的重大轉變，尤其是隨著數位避孕的興起。這種創新方法使用戶能夠透過線上平台監測月經週期並評估懷孕風險。由女性科技公司和其他機構開發的數位避孕解決方案利用預測演算法，幫助用戶就其性健康做出明智的決定，從而改善預防策略並實現避孕方法的個人化。隨著越來越多的消費者提高健康意識和科技素養，對數位解決方案的需求預計將會成長，這將改變避孕選擇的格局，並提高生殖健康管理的可及性和用戶參與度。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

全球避孕藥具市場規模（按類型及複合年成長率分類）（2026-2033 年）

• 口服避孕藥
• 複方口服避孕藥
• 僅含黃體素的片劑
• 局部避孕藥
• 避孕針
• 其他

全球避孕藥具市場規模（按分銷類型和複合年成長率分類）（2026-2033 年）

• 醫院和診所
• 零售藥房
• 網路藥房
• 其他

全球避孕藥具市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2021-2023年營收年比比較

主要企業簡介

• Pfizer Inc.（USA）
• Bayer AG（Germany）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Mylan NV（Netherlands）
• Novartis AG（Switzerland）
• Johnson & Johnson（USA）
• GlaxoSmithKline plc（UK）
• Allergan plc（Ireland）
• Agile Therapeutics, Inc.（USA）
• Piramal Healthcare（India）
• Organon & Co.（Netherlands）
• HRA Pharma（France）
• CooperSurgical, Inc.（USA）
• Church & Dwight Co., Inc.（USA）
• Merck & Co., Inc.（USA）
• Famy Care Ltd.（India）
• Sinopharm Group Co., Ltd.（China）
• Sun Pharmaceutical Industries Ltd.（India）
• Torrent Pharmaceuticals Ltd.（India）
• Dr. Reddy's Laboratories Ltd.（India）

結論與建議

Contraceptive Drugs Market size was valued at USD 34022.89 Million in 2024 and is poised to grow from USD 36234.38 Million in 2025 to USD 59967.75 Million by 2033, growing at a CAGR of 6.5% during the forecast period (2026-2033).

The contraceptive drugs market is poised for growth driven by rising incidences of sexually transmitted diseases and a significant number of women desiring contraceptive solutions. A considerable global population of women of reproductive age expresses a need for family planning, with millions currently utilizing contraceptive methods while many others remain with unmet demand. Efforts to implement targeted programs aimed at reducing unplanned pregnancies and enhancing awareness around contraceptive options are anticipated to propel market expansion. Nevertheless, concerns regarding side effects such as gastrointestinal issues, weight changes, and emotional effects related to various contraceptive methods may hinder growth. Additionally, the increasing rates of infertility and inconsistent sex education in developed regions pose challenges to the market's advancement.

Top-down and bottom-up approaches were used to estimate and validate the size of the Contraceptive Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Contraceptive Drugs Market Segments Analysis

Global Contraceptive Drugs Market is segmented by type, distribution and region. Based on type, the market is segmented into oral contraceptives, combined oral contraceptive pills, progestogen-only pills, topical contraceptives, contraceptive injectable and others. Based on distribution, the market is segmented into hospital & clinics, retail pharmacy, online pharmacy and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Contraceptive Drugs Market

The prevalence of unintended pregnancies is notably high among poorer and low-income populations globally. A major contributor to this issue is the reliance on traditional contraceptive methods, which are often less effective. This scenario leads to a troubling incidence of unsafe abortions and maternal mortality. In regions such as Latin America, young teenagers face a significantly elevated risk of maternal death compared to older women. Consequently, the adoption of contraceptive drugs plays a vital role in reducing the rates of unplanned pregnancies, thereby improving maternal health outcomes and ensuring better reproductive choices for individuals in these vulnerable groups.

Restraints in the Contraceptive Drugs Market

The contraceptive drugs market faces significant challenges due to the side effects associated with prolonged use of birth control pills, which can include headaches, abnormal bleeding, and nausea. These potential adverse effects, particularly after extended use, raise concerns among consumers. Additionally, medications that contain estrogen and progesterone carry an increased risk of developing blood clots, which can result in serious health complications such as heart attacks. Consequently, these safety concerns contribute to consumer hesitance and may impede the expansion and acceptance of contraceptive pharmaceuticals in the market, limiting its overall growth potential.

Market Trends of the Contraceptive Drugs Market

The contraceptive drugs market is witnessing a significant shift towards technological advancements, particularly with the rise of digital contraception. This innovative approach allows individuals to monitor their menstrual cycles and assess pregnancy risk through online platforms. By leveraging predictive algorithms, digital contraceptive solutions, such as those developed by femtech companies, enable users to make informed decisions about their sexual health, improving prevention strategies and personalizing contraceptive methods. As more consumers become health-conscious and tech-savvy, the demand for digital solutions is anticipated to grow, reshaping the landscape of contraceptive options and enhancing accessibility and user engagement in reproductive health management.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Contraceptive Drugs Market Size by Type & CAGR (2026-2033)

• Market Overview
• Oral Contraceptives
• Combined Oral Contraceptive Pills
• Progestogen-Only Pills
• Topical Contraceptives
• Contraceptive Injectable
• Others

Global Contraceptive Drugs Market Size by Distribution & CAGR (2026-2033)

• Market Overview
• Hospital & Clinics
• Retail Pharmacy
• Online Pharmacy
• Others

Global Contraceptive Drugs Market Size & CAGR (2026-2033)

• North America (Type, Distribution)
  • USA
  • Canada
• Europe (Type, Distribution)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Distribution)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Distribution)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Distribution)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agile Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Piramal Healthcare (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Organon & Co. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• HRA Pharma (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CooperSurgical, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Church & Dwight Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Famy Care Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sinopharm Group Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Torrent Pharmaceuticals Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations